Preventive health offering combines ‘microdosed’ GLP-1 meds with biomarker monitoring and behavior change guidance.
Digital health platform Noom is broadening its business beyond weight management with today’s launch of a preventive health and longevity program that combines microdoses of GLP-1 medication with behavior change and biomarker monitoring. The new program reflects the company’s strategic shift toward addressing metabolic and cardiovascular risk earlier, targeting people who may not meet traditional criteria for obesity treatment but show biological signs associated with future disease.
“The problem we’re solving is that most Americans are living with suboptimal health – and their blood biomarkers show it,” said Noom CMO Dr Jeffrey Egler. “That eventually manifests as chronic disease. In the United States today, roughly three in four adults in midlife are living with at least one chronic health condition.”
The latest Noom program combines three main elements: personalized, low-dose GLP-1 prescriptions; regular at-home blood testing; and ongoing digital behavior-change support delivered through the company’s app. The goal is to help users understand and improve biomarkers linked to their cardiometabolic health, inflammation, and aging before chronic conditions develop.
While most GLP-1 programs are focused primarily on weight loss and intended for clinically obese people, eligibility Noom’s new offering begins at a body mass index of 21 or higher, which encompasses most US adults. Starting doses are set at roughly a quarter of the lowest starting dose used in Noom’s other GLP-1 programs. The company cites third-party research and its own data indicating that the new dosage levels can influence metabolic biomarkers such as HbA1c, which has been linked to cardiovascular disease, cognitive aging, liver fat accumulation, kidney function, inflammation, fertility outcomes and mortality.
“Today marks the start of a new era for Noom,” said Noom CEO Geoff Cook, highlighting presentations made at the recent AARD conference in Copenhagen where GLP-1s were described as longevity drugs. “Now, we can intervene sooner. We can get in front of chronic disease and reach people before metabolic disorder takes root.”
A central component of Noom’s program is routine biomarker monitoring. Members receive an at-home blood testing kit every four months. The test panel includes 17 markers covering metabolic, cardiovascular, hormonal, inflammatory and nutritional domains. By repeating testing several times a year, Noom aims to help users see how medication use and daily habits affect their internal health over relatively short intervals.
The digital longevity companion within the Noom app emphasizes daily microhabits related to nutrition, physical activity, stress management, and self-monitoring. The platform incorporates cognitive behavioral therapy techniques, alongside features such as AI-assisted food logging, body composition scanning and goal tracking.
“By pairing healthy habits with microdosed medication, we aim to help members both understand and improve their biomarkers – and their long-term health – before disease develops,” said Egler.
Noom argues that the behavior change component is particularly important given high discontinuation rates for GLP-1 medications across the market and claims it is attempting to create durability beyond the period of pharmacologic support.
“GLP-1s can lower food noise and may boost self-efficacy for health,” said Cook. “Action produces results, results fuel motivation, and motivation transforms identity. Health becomes habit, not effort. When identity begins to shift, the door opens to broader transformation. The question becomes ‘What else can I improve?’”
Noom’s new program is called Proactive Health Microdose GLP-1Rx and is priced at $149 per month.
“The old healthcare model waited for disease and treated symptoms,” said Egler. “The new era is proactive – integrating biology, psychology, and technology to prevent disease before it starts. GLP-1s are not a shortcut – they’re the spark. They open the door for change, but actively walking through that door is what makes the transformation last.”
